Key clinical point: Subcutaneous nemolizumab significantly improved pruritus in atopic dermatitis patients who were resistant to topical treatments.
Major finding: The average change in visual analog scale Score was –42.8% for nemolizumab patients and –21.4% for placebo patients.
Study details: The data come from a phase 3, randomized trial of 143 Japanese adults with atopic dermatitis.
Disclosures: The study was supported by Maruho. Dr. Kabashima disclosed consulting fees from Maruho and two coauthors were Maruho employees.
Kabashima K et al. N Engl J Med. 2020 Jul 9. doi: 10.1056/NEJMoa1917006.